Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 472 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Irene Becklund sold 472 shares of Hims & Hers Health stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.58, for a total value of $13,961.76. Following the completion of the sale, the insider now directly owns 17,331 shares in the company, valued at $512,650.98. This trade represents a 2.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Irene Becklund also recently made the following trade(s):

• On Monday, November 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.42, for a total transaction of $9,166.24.

Hims & Hers Health Trading Down 0.4 %

HIMS traded down $0.13 during trading hours on Tuesday, hitting $31.12. The company's stock had a trading volume of 14,635,490 shares, compared to its average volume of 9,946,161. Hims & Hers Health, Inc. has a fifty-two week low of $8.09 and a fifty-two week high of $35.02. The firm has a market capitalization of $6.80 billion, a PE ratio of 70.09 and a beta of 1.25. The company has a 50-day simple moving average of $25.02 and a 200 day simple moving average of $21.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the company earned ($0.04) EPS. The firm's quarterly revenue was up 77.1% on a year-over-year basis. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HIMS shares. Bank of America downgraded shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and cut their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. TD Cowen reissued a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Morgan Stanley assumed coverage on shares of Hims & Hers Health in a report on Tuesday. They issued an "overweight" rating and a $42.00 price target on the stock. Piper Sandler reiterated a "neutral" rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $22.80.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the last quarter. State Street Corp lifted its stake in Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after buying an additional 206,078 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after buying an additional 482,177 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after buying an additional 883,230 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company's stock worth $30,714,000 after acquiring an additional 218,566 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.